Short answer
DiaMedica Therapeutics Inc. (DMAC) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$9M
- −37.4% YoY · −12.0% QoQ
- EPS (diluted)
- −$0.17
- −13.3% YoY · +5.6% QoQ
Source: XBRL data from the DiaMedica Therapeutics Inc. (DMAC) Q3 2025 10-Q on SEC EDGAR. USD.
DiaMedica Therapeutics Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $0 for the quarter and prior-year quarter
- Net loss $24.0M for nine months vs $16.5M YoY
- R&D expenses $6.4M vs $5.0M YoY
- Cash, equivalents and securities $55.3M vs $44.1M at December 31, 2024
- Operating cash use $21.3M vs $15.6M YoY; July financing net proceeds $30.0M; ReMEDy2 interim analysis targeted second half 2026
Risk Factors
- New trial-replication risk triggered by promising interim Part 1a preeclampsia data for investigator-sponsored Phase 2 DM199 study
- Most material update: interim DM199 results may differ from final analysis or fail replication in ongoing and future trials
- FDA review risk from administration policies involving workforce downsizing, communication limits, and potential user-fee reauthorization impacts
- Regulatory approval risk if later DM199 trials miss endpoints or produce a restricted product label
- Government-agency funding and staffing reductions potentially delaying regulatory submissions and commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other DiaMedica Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.